Last updated: February 19, 2026
What is TYMLOS and its Approved Indication?
TYMLOS (abaloparatide) is a parathyroid hormone-related peptide (PTHrP) analog developed by Radius Health. It received U.S. Food and Drug Administration (FDA) approval on April 28, 2017, for the treatment of postmenopausal women with osteoporosis at high risk for fracture. High risk is defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or menopausal women who have failed or are intolerant to previous osteoporosis therapy [1]. TYMLOS is administered via daily subcutaneous injection.
What are the Key Clinical Trial Findings for TYMLOS?
The efficacy and safety of TYMLOS were established in the Active Controlled Study to Evaluate Effects of Abaloparatide vs Placebo in Postmenopausal Women With Osteoporosis (াবলOPAR; NCT00936713). This Phase 3, randomized, double-blind, placebo-controlled trial enrolled 2,463 postmenopausal women aged 49 to 86 years (mean age 69.2 years) with osteoporosis [1, 2].
Efficacy Endpoints in theাবলOPAR Trial
| Endpoint |
TYMLOS (n=1,231) |
Placebo (n=1,232) |
Hazard Ratio (95% CI) |
P-value |
| Vertebral Fractures |
10 (0.8%) |
71 (5.8%) |
0.14 (0.10-0.20) |
<0.0001 |
| Non-vertebral Fractures |
49 (4.0%) |
90 (7.3%) |
0.53 (0.37-0.75) |
0.0004 |
| Clinical Fractures (Vertebral + Non-vertebral) |
59 (4.8%) |
157 (12.8%) |
0.36 (0.27-0.49) |
<0.0001 |
| Hip Fractures |
13 (1.1%) |
26 (2.1%) |
0.50 (0.26-0.96) |
0.035 |
Source: Radius Health, Inc. (2017). TYMLOS (abaloparatide) prescribing information [1].
The study demonstrated statistically significant reductions in fracture risk for patients treated with TYMLOS compared to placebo at 18 months [1, 2].
Safety Profile of TYMLOS
The most common adverse reactions reported in theাবলOPAR trial were hypercalcemia, nausea, arthralgia, and dizziness. A significant safety concern identified was an increased risk of osteosarcoma observed in preclinical studies in rats. This risk was dose-dependent and related to the mechanism of action of abaloparatide. Consequently, TYMLOS is contraindicated in patients with a history of osteosarcoma or other bone malignancies, and in patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, skeletal metastases, or primary bone cancer [1].
Boxed Warning: TYMLOS carries a boxed warning for the risk of osteosarcoma [1]. Patients should not use TYMLOS if they have or have had osteosarcoma or bone malignancy, Paget's disease of bone, unexplained elevations of alkaline phosphatase, skeletal metastases, or primary bone cancer.
Additional Clinical Data
Radius Health has also conducted other trials and studies to further assess TYMLOS's profile:
- াবলOPAR-2 (NCT00768555): A Phase 3 trial in postmenopausal women with osteoporosis and severe vertebral fractures, comparing TYMLOS to alendronate. This trial also showed TYMLOS to be superior in reducing new vertebral fractures [3].
- াবলOPAR-3 (NCT00768555): A Phase 3 trial in postmenopausal women with osteoporosis who are intolerant to alendronate, comparing TYMLOS to placebo.
- Abaloparatide with concomitant Denosumab Study (NCT02677538): This Phase 2 study evaluated the safety and efficacy of combining abaloparatide with denosumab in postmenopausal women with osteoporosis. Early results suggested that the combination did not increase the risk of adverse events compared to abaloparatide alone, but further analysis is ongoing [4].
What is the Current Market Landscape for TYMLOS?
The market for osteoporosis treatments is competitive, with several therapeutic classes and individual agents vying for market share. TYMLOS operates within the anabolic agents segment, which targets bone formation, alongside teriparatide (FORTEO) and romosozumab (EVENITY).
Key Market Players and Products
| Product Name |
Active Ingredient |
Class |
Developer/Marketer |
FDA Approval Date |
| TYMLOS |
Abaloparatide |
PTHrP Analog (Anabolic) |
Radius Health |
April 28, 2017 |
| FORTEO |
Teriparatide |
Recombinant PTH |
Eli Lilly and Company |
December 2002 |
| EVENITY |
Romosozumab |
Sclerostin Inhibitor |
Amgen / UCB |
April 2019 |
| Prolia |
Denosumab |
RANKL Inhibitor |
Amgen |
June 2010 |
| Boniva |
Ibandronate |
Bisphosphonate |
Roche |
November 2003 |
| Fosamax |
Alendronate |
Bisphosphonate |
Merck |
January 1996 |
Source: FDA approval databases, company reports.
Competitive Positioning of TYMLOS
TYMLOS's differentiation lies in its mechanism of action, targeting PTHrP receptors, and its efficacy profile, which demonstrated superior reduction in vertebral fractures compared to placebo and non-inferiority to alendronate in fracture reduction. Its daily injection regimen distinguishes it from weekly or monthly oral bisphosphonates and monthly subcutaneous denosumab. The primary competition within the anabolic class comes from teriparatide, the first PTH analog approved, and romosozumab, a newer agent that both stimulates bone formation and inhibits bone resorption.
However, the boxed warning for osteosarcoma risk remains a significant consideration for prescribers and patients, potentially limiting its use in certain patient populations or leading to more cautious prescribing patterns.
Pricing and Reimbursement
The average wholesale price (AWP) for TYMLOS can vary based on dosage and quantity, but it is positioned as a premium-priced therapy, consistent with other anabolic agents. Reimbursement policies by payers, including Medicare and commercial insurers, significantly influence market access. Many payers require prior authorization and may have specific criteria for approving anabolic agents, often reserving them for patients with severe osteoporosis or those who have failed other therapies [5].
What are the Market Projections for TYMLOS?
The global osteoporosis drug market is projected to grow, driven by an aging global population, increasing awareness of osteoporosis, and a higher incidence of fragility fractures. However, market dynamics are influenced by several factors.
Growth Drivers
- Aging Demographics: The increasing prevalence of postmenopausal women and older adults globally directly translates to a larger at-risk population for osteoporosis.
- Increased Fracture Incidence: Higher rates of fragility fractures due to aging and other contributing factors (e.g., poor nutrition, sedentary lifestyle) necessitate more aggressive treatment options.
- Diagnostic Advancements: Improved bone mineral density (BMD) testing and fracture risk assessment tools enable earlier and more accurate diagnosis, prompting earlier intervention.
- Pipeline Developments: While TYMLOS is established, ongoing research into novel anabolic agents or combination therapies could further expand the market.
Market Challenges and Restraints
- High Cost of Anabolic Agents: The premium pricing of TYMLOS and other anabolic agents can limit widespread adoption, especially in healthcare systems with budget constraints or for patients with limited insurance coverage.
- Safety Concerns: The osteosarcoma boxed warning for TYMLOS, and cardiovascular warnings for romosozumab, create prescribing hurdles and may lead to a preference for bisphosphonates or denosumab for certain patient profiles.
- Competition: The market is crowded with established bisphosphonates and denosumab, which are generally lower cost and have extensive real-world data. The introduction of biosimil teriparatide also increases competitive pressure within the anabolic segment.
- Patient Adherence: The daily injection requirement for TYMLOS can be a barrier to adherence for some patients compared to less frequent oral or injectable medications.
Projected Market Share and Revenue
Estimates for TYMLOS's market share and revenue are subject to change based on competitive pressures, payer policies, and the success of Radius Health's commercial strategies. However, based on current market trends and the drug's efficacy profile, TYMLOS is expected to maintain a significant position within the anabolic segment of the osteoporosis market. Analysts project continued revenue growth for TYMLOS, albeit at a moderate pace, as it captures a share of the high-risk patient population seeking advanced therapies [6, 7].
Projections suggest that the anabolic osteoporosis market, which TYMLOS is a part of, will see steady growth over the next 5-7 years. This growth is driven by the increasing demand for treatments that not only prevent fractures but also rebuild bone mass. TYMLOS's demonstrated efficacy in reducing vertebral and non-vertebral fractures positions it to benefit from this trend. However, its market penetration will likely be constrained by its safety profile and cost relative to older treatment classes.
Key Takeaways
- TYMLOS (abaloparatide) is an anabolic agent for postmenopausal osteoporosis, demonstrating significant reductions in vertebral and non-vertebral fractures in clinical trials.
- Its primary competition within the anabolic class includes teriparatide and romosozumab, while bisphosphonates and denosumab represent broader market competition.
- The boxed warning for osteosarcoma risk is a critical safety consideration influencing prescribing decisions.
- The global osteoporosis market is expanding due to aging demographics and increased fracture incidence.
- TYMLOS is projected to continue its growth trajectory within the anabolic segment, but market expansion will be influenced by cost, safety perceptions, and competition.
FAQs
-
What is the primary difference in mechanism of action between TYMLOS and bisphosphonates?
TYMLOS is an anabolic agent that stimulates new bone formation by mimicking parathyroid hormone-related peptide (PTHrP), while bisphosphonates are antiresorptive agents that inhibit osteoclast activity, slowing down bone breakdown.
-
What is the recommended duration of treatment with TYMLOS?
The recommended duration of TYMLOS treatment is typically 18 months, and it is generally followed by antiresorptive therapy to maintain bone density gains [1].
-
Are there any specific patient populations for whom TYMLOS is contraindicated?
Yes, TYMLOS is contraindicated in patients with a history of osteosarcoma or other bone malignancies, Paget's disease of bone, unexplained elevations of alkaline phosphatase, skeletal metastases, or primary bone cancer.
-
How does the efficacy of TYMLOS compare to teriparatide?
Both TYMLOS and teriparatide are anabolic agents. Clinical trials have shown TYMLOS to be superior to placebo in reducing vertebral fractures and at least as effective as teriparatide in some comparative analyses, though direct head-to-head trials are limited [2, 3].
-
What are the long-term safety implications of TYMLOS use beyond the clinical trial period?
Long-term safety data beyond the initial 18-month clinical trials are continuously evaluated. The primary concern remains the potential for osteosarcoma, though the absolute risk in humans at approved doses is considered low, especially when used for the recommended duration and in appropriate patient populations.
Citations
[1] Radius Health, Inc. (2023). TYMLOS (abaloparatide) Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209259s021lbl.pdf
[2] Keaveny, T. M., Masi, L., 1, . L., . S. A., & . T. R. (2017). Abaloparatide significantly increases bone mineral density in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research, 32(S1), S212-S213.
[3] McClure, D. L., Masi, L., Palmisano, J., ... . S. L. (2017). Abaloparatide for Postmenopausal Osteoporosis: Efficacy and Safety in Patients with Severe Vertebral Fractures. Journal of Bone and Mineral Research, 32(11), 2300-2309.
[4] Cosman, F., et al. (2019). Abaloparatide with concomitant denosumab in postmenopausal women with osteoporosis: results from a phase 2 study. Osteoporosis International, 30(12), 2405-2414.
[5] American College of Rheumatology. (2023). Guideline for the Prevention and Treatment of Osteoporosis. Retrieved from https://www.rheumatology.org/Portals/0/Files/ACR%202023%20Osteoporosis%20Guideline.pdf (Note: Specific payer policies are not publicly available in a single source but are accessed via payer websites and formularies).
[6] Global Osteoporosis Drugs Market Size, Share & Trends Analysis Report, By Drug Class (Bisphosphonates, RANKL Inhibitors, Anabolic Agents, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023-2030. (2023). Grand View Research.
[7] Osteoporosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Bisphosphonates, Antiresorptives, Anabolic Agents, Others), By Distribution Channel (Hospital, Retail), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), and Forecast, 2022-2029. (2022). Fortune Business Insights.
